The stream of companies undergoing inversions will continue until the U.S. moves to territorial taxation coupled with a lower U.S. corporate tax rate, said Tim Larson, Partner-in-Charge of Tax & Business Services at Marcum. Larson said he does not expect Congress to take such a large step anytime soon so companies, especially in the pharmaceutical sector, will continue to try and redomecile abroad. Larson said tax inversion is not a new strategy for companies seeking a competitive advantage because it was prevalent in the energy sector 20-30 years ago. Finally, Larson said he expects technology companies to follow the path of pharma firms because they have fewer tangible assets abroad, but lots of cash.

More from Video

Video: This One Mathematical Concept Can Make You a Millionaire

Video: This One Mathematical Concept Can Make You a Millionaire

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Alpha Rising: Paralyzed Powerhouse M&A Attorney: "I Will Walk Again"

Alpha Rising: Paralyzed Powerhouse M&A Attorney: "I Will Walk Again"

Video: Jim Cramer on Apple, Procter & Gamble, Nucor and Acacia Communications

Video: Jim Cramer on Apple, Procter & Gamble, Nucor and Acacia Communications

Jim Cramer on Acacia Communications: Read the 10-K Report

Jim Cramer on Acacia Communications: Read the 10-K Report